N4 Pharma achieves material advancements in the capabilities of Nuvec®
N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced its audited results for the year ended 31 December 2023.